TY - JOUR
T1 - Chemical biology of compounds obtained from screening using disease models
AU - Tashiro, Estu
AU - Imoto, Masaya
N1 - Publisher Copyright:
© 2015 The Pharmaceutical Society of Korea.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Bioactive compounds are extremely powerful tools for studying biological systems because they can rapidly, conditionally, often reversibly, and dose-dependently modulate the biological function of living cells. Moreover, they are expected to be drug seeds for chemotherapy of several diseases. Two approaches are used to find and obtain bioactive compounds, namely, molecular-target-based screening and phenotypic screening. Through phenotypic screening that mimics tumor metastasis, multi-drug resistance, and Parkinson's disease, we identified several compounds that inhibit cancer cell migration, anti-apoptotic function of Bcl-2/Bcl-xL, and neuronal cell death. By using MEK inhibitor that was developed by target-based screening, we discovered that MEK inhibitor selectively induces apoptosis in tumor cells with β-catenin mutation. Using target-based screening, we identified arabilin, a novel androgen antagonist. In this review, we introduce our recent studies on the identification of bioactive compounds by phenotypic screening and by target-based screening for drug-seed discovery.
AB - Bioactive compounds are extremely powerful tools for studying biological systems because they can rapidly, conditionally, often reversibly, and dose-dependently modulate the biological function of living cells. Moreover, they are expected to be drug seeds for chemotherapy of several diseases. Two approaches are used to find and obtain bioactive compounds, namely, molecular-target-based screening and phenotypic screening. Through phenotypic screening that mimics tumor metastasis, multi-drug resistance, and Parkinson's disease, we identified several compounds that inhibit cancer cell migration, anti-apoptotic function of Bcl-2/Bcl-xL, and neuronal cell death. By using MEK inhibitor that was developed by target-based screening, we discovered that MEK inhibitor selectively induces apoptosis in tumor cells with β-catenin mutation. Using target-based screening, we identified arabilin, a novel androgen antagonist. In this review, we introduce our recent studies on the identification of bioactive compounds by phenotypic screening and by target-based screening for drug-seed discovery.
KW - Androgen
KW - Apoptosis
KW - Cell migration
KW - MEK
KW - Parkinson's disease
KW - β-Catenin
UR - http://www.scopus.com/inward/record.url?scp=84942198139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942198139&partnerID=8YFLogxK
U2 - 10.1007/s12272-015-0633-4
DO - 10.1007/s12272-015-0633-4
M3 - Article
C2 - 26177809
AN - SCOPUS:84942198139
SN - 0253-6269
VL - 38
SP - 1651
EP - 1660
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 9
M1 - 633
ER -